Multiple Sclerosis CAR T Therapy Moves Toward Immune Reset
Early human studies suggest CAR T-cell therapy may one day help selected people with multiple sclerosis and other autoimmune diseases
CAR T-cell therapy, first developed for blood cancers, is now being tested in autoimmune diseases such as multiple sclerosis, lupus, stiff person syndrome, and myasthenia gravis. The most important idea is simple: instead of only suppressing inflammation again and again, researchers are testing whether engineered immune cells can remove the immune cells driving disease and give the immune system a partial reset. This remains experimental for multiple sclerosis and should be viewed as a clinical-trial strategy, not an approved treatment.
Study Details
The article centers on Jan Janisch-Hanzlik, a 49-year-old woman with multiple sclerosis whose symptoms were worsening despite available medication. She became the first person with MS treated with an allogeneic, or donor-derived, CAR T-cell therapy at Nebraska Medicine in June 2025. UNMC described the approach as a first-of-its-kind MS trial using genetically modified donor T cells to target immune cells involved in MS-related inflammation and damage.
The therapy being studied, azercabtagene zapreleucel, also called azer-cel, is an investigational anti-CD19 allogeneic CAR T-cell therapy. CD19 is a marker found across B-cell lineages, and B cells are increasingly understood as important drivers in several autoimmune diseases. TG Therapeutics says azer-cel is in a Phase 1 trial designed to assess safety, tolerability, and early clinical activity in MS and other immune-mediated neurological conditions.
This is part of a bigger shift in medicine. CAR T is no longer just a cancer story. Researchers are now asking whether the same immune-cell engineering concept can be adapted for diseases where the immune system attacks the body itself.
Methodology
For the MS trial, the treatment uses donor T cells rather than the patient’s own T cells. These cells are engineered to recognize CD19-positive B cells, then infused after a short course of chemotherapy to prepare the immune system. The goal is to remove disease-driving immune cells and observe whether symptoms, disease activity, and immune markers improve over time.
This differs from traditional autologous CAR T, where each patient’s own T cells are collected, engineered, expanded, and returned. The off-the-shelf approach could eventually be faster and more scalable, but it also creates its own risks, including immune mismatch and the need for careful gene-editing safeguards.
Other autoimmune CAR T strategies are also being tested. In myasthenia gravis, a Phase 2b trial of Descartes-08, an RNA-encoded BCMA-directed CAR T therapy, reported a higher clinical response rate at month 3 than placebo, with durable improvement in several disease scores through follow-up. Importantly, that approach used mRNA-based engineering and did not require lymphodepleting chemotherapy in that trial.
Key Findings
For MS, this is early but important. The Nebraska case shows that allogeneic CAR T has now moved into human testing for progressive MS, but it is still Phase 1 research focused first on safety.
The target is the immune system’s B-cell machinery. Azer-cel targets CD19-positive B cells, which may contribute to autoimmune inflammation in MS and other B-cell mediated diseases.
The patient story is encouraging but not proof. Janisch-Hanzlik reportedly had no major side effects in follow-up and later noticed improvements such as less double vision, less need for a cane, fewer falls, and less fatigue, while still having symptoms such as leg weakness and numbness.
Other autoimmune trials add credibility to the direction. In generalized myasthenia gravis, Descartes-08 showed 66.7% MGC responders at month 3 versus 27.3% with placebo in a randomized Phase 2b trial.
Safety remains the gating issue. CAR T can trigger serious inflammatory reactions, infection risk, immune suppression, neurotoxicity concerns, and possible long-term toxicities. FDA officials have emphasized long-term monitoring as CAR T expands into autoimmune diseases.
Implications for Practice
For patients with multiple sclerosis, the message is hopeful but cautious. CAR T is not ready to replace current MS disease-modifying therapies. It is not a routine treatment option. But for people with progressive or treatment-resistant disease, this research opens a new category of thinking: instead of continuously managing the autoimmune fire, can medicine remove some of the immune cells helping keep that fire alive?
For neurologists and immunologists, the practical question is patient selection. CAR T may make the most sense first in severe, refractory, or progressive autoimmune disease where existing options are not enough and where the risk-benefit balance may justify a more intensive intervention. That is very different from using it broadly in stable patients.
For healthcare systems, the major constraint will be operational. CAR T requires specialized centers, close monitoring, infection prevention, trained teams, and long-term follow-up. Off-the-shelf and mRNA CAR T approaches may reduce some barriers, but they do not remove the need for careful infrastructure.
For researchers, this is now a platform question. CD19, BCMA, autologous cells, donor cells, mRNA engineering, in-vivo CAR T, and switchable CAR T are different design choices. The winning approach may not simply be the strongest immune reset. It may be the approach that balances efficacy, safety, reversibility, cost, and repeatability.
Bottom Line
CAR T therapy for autoimmune disease is moving from theory into human trials. For multiple sclerosis, the Nebraska case is an early signal, not a conclusion. The promise is a deeper immune reset. The caution is that resetting the immune system is not a small intervention. For now, this belongs in carefully monitored clinical trials, but it is one of the most important treatment directions to watch in autoimmune medicine.